News | September 28, 2006

Statins Before Surgery May Prevent AF

Administering a cholesterol-lowering drug prior to heart bypass surgery or surgical repair of a faulty heart valve may reduce the occurrence of atrial fibrillation, a common heart rhythm disturbance triggered by these surgeries. The research was published in “Circulation: Journal of the American Heart Association.”

About 2 million people in America and 4.5 million in Europe have AF, according to a recent joint scientific statement from the American Heart Association, American College of Cardiology and the European Society of Cardiology.

“Daily treatment with 40 mg of atorvastatin (Lipitor) for seven days before heart surgery reduced the risk of postoperative AF by 61 percent compared to patients who received a placebo for seven days,” said Giuseppe Patti, M.D., lead author of the study and assistant professor of cardiology in the Department of Cardiovascular Sciences at Campus Bio-Medico University in Rome, Italy.

Atorvastatin is in a class of medications called HMG-CoA reductase inhibitors (statins). It works by slowing the body’s production of cholesterol.

For more information, visit www.americanheart.org.

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
CardioFocus Announces European CE Mark Approval of HeartLight Excalibur Balloon
Technology | Ablation Systems| October 10, 2017
October 10, 2017 — CardioFocus Inc. recently announced the European CE Mark approval of the HeartLight Excalibur Ball
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
The Apama Radiofrequency (RF) Balloon Catheter System.
News | Ablation Systems| October 02, 2017
October 2, 2017 — Boston Scientific announced a definitive agreement to acquire Apama Medical Inc., a privately-held
Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Spectranetics Initiates Class I Recall for Bridge Occlusion Balloon Catheter
News | EP Lab| September 27, 2017
Spectranetics is recalling its Bridge Occlusion Balloon Catheter due to the possibility of a blocked guidewire lumen in...
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
Overlay Init